Journal of Surgery Concepts & Practice >

2023 , Vol. 28 >Issue 05: 483 - 487

DOI: https://doi.org/10.16139/j.1007-9610.2023.05.15

Review

Current status and prospect of CAR-T cell immunotherapy for colorectal cancer

Expand
  • Department of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China

Received date: 2022-11-18

  Online published: 2024-01-04

Fold

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy is a new method of immunotherapy for cancer that has achieved remarkable results in treating blood tumors. However, colorectal cancer(CRC), as a solid tumor, has different characteristics from hematological tumors, which impose certain constraints on the selection of its therapeutic targets and the effectiveness of treatment of CAR-T therapy. Therefore, it is necessary to select therapeutic targets with high specificity and effectiveness according to the characteristics of CRC, as well as to break through the constraints such as adverse effects caused by the treatment and the solid tumor microenvironment, to make CAR-T therapy applicable in the treatment of CRC. This article aimed to summarize the strategy of selecting therapeutic targets for CAR-T cell immunotherapy for CRC, analyze the restrictive factors of this therapy in the treatment of CRC, and forecast the prospect of CAR-T cell immunotherapy for CRC.

Key words： Chimeric antigen receptor T cell; Colorectal cancer; Immunotherapy

Cite this article

ZHANG Tianshuai, ZHOU Leqi, YU Guanyu, ZHANG Wei . Current status and prospect of CAR-T cell immunotherapy for colorectal cancer[J]. Journal of Surgery Concepts & Practice, 2023 , 28(05) : 483 -487 . DOI: 10.16139/j.1007-9610.2023.05.15

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] SIDDIQUI R S, SARDAR M. A systematic review of the role of chimeric antigen receptor T (CAR-T) cell therapy in the treatment of solid tumors[J]. Cureus, 2021, 13(4):e14494.
[3] COUZIN-FRANKEL J. Breakthrough of the year 2013.Cancer immunotherapy[J]. Science, 2013, 342(6165):1432-1433.
[4] STERNER R C, STERNER R M. CAR-T cell therapy: current limitations and potential strategies[J]. Blood Cancer J, 2021, 11(4):69.
[5] QI C, GONG J, LI J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Nat Med, 2022, 28(6):1189-1198.
[6] SUR D, HAVASI A, CAINAP C, et al. Chimeric antigen receptor T-cell therapy for colorectal cancer[J]. J Clin Med, 2020, 9(1):182.
[7] CREES Z D, GHOBADI A. Cellular therapy updates in B-cell lymphoma: the state of the CAR-T[J]. Cancers (Basel), 2021, 13(20):5181.
[8] MARTINEZ M, MOON E K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment[J]. Front Immunol, 2019, 10:128.
[9] SNOOK A E, MAGEE M S, WALDMAN S A. GUCY2C-targeted cancer immunotherapy: past, present and future[J]. Immunol Res, 2011, 51(2-3):161-169.
[10] MAGEE M S, ABRAHAM T S, BAYBUTT T R, et al. Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases[J]. Cancer Immunol Res, 2018, 6(5):509-516.
[11] HAMMARSTR?M S. The carcinoembryonic antigen(CEA) family: structures, suggested functions and expression in normal and malignant tissues[J]. Semin Cancer Biol, 1999, 9(2):67-81.
[12] HALL C, CLARKE L, PAL A, et al. A review of the role of carcinoembryonic antigen in clinical practice[J]. Ann Coloproctol, 2019, 35(6):294-305.
[13] XU J, MENG Q, SUN H, et al. HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer[J]. Cell Death Dis, 2021, 12(12):1109.
[14] LI W, ZHOU Y, WU Z, et al. Targeting Wnt signaling in the tumor immune microenvironment to enhancing EpCAM CAR T-Cell therapy[J]. Front Pharmacol, 2021, 12:724306.
[15] ZHANG B L, LI D, GONG Y L, et al. Preclinical evaluation of chimeric antigen receptor-modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer[J]. Hum Gene Ther, 2019, 30(4):402-412.
[16] DARCY P K, HAYNES N M, SNOOK M B, et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL[J]. J Immunol, 2000, 164(7):3705-3712.
[17] ZHANG C, WANG Z, YANG Z, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers[J]. Mol Ther, 2017, 25(5):1248-1258.
[18] MORELLO A, SADELAIN M, ADUSUMILLI P S. Mesothelin-targeted CARs: driving T cells to solid tumors[J]. Cancer Discov, 2016, 6(2):133-146.
[19] ZHANG Q, LIU G, LIU J, et al. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice[J]. Mol Ther Oncolytics, 2021, 20:556-568.
[20] FREY N, PORTER D. Cytokine release syndrome with chimeric antigen receptor T cell therapy[J]. Biol Blood Marrow Transplant, 2019, 25(4):e123-e127.
[21] FREYER C W, PORTER D L. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies[J]. J Allergy Clin Immunol, 2020, 146(5):940-948.
[22] AHMED N, BRAWLEY V S, HEGDE M, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma[J]. J Clin Oncol, 2015, 33(15):1688-1696.
[23] MORGAN R A, YANG J C, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J]. Mol Ther, 2010, 18(4):843-851.
[24] PARKHURST M R, YANG J C, Langan R C, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis[J]. Mol Ther, 2011, 19(3):620-626.
[25] BHOWMICK N A, NEILSON E G, Moses H L. Stromal fibroblasts in cancer initiation and progression[J]. Nature, 2004, 432(7015):332-337.
[26] LIU G, RUI W, ZHAO X, et al. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment[J]. Cell Mol Immunol, 2021, 18(5):1085-1095.
[27] BIFFI G, TUVESON D A. Diversity and biology of cancer-associated fibroblasts[J]. Physiol Rev, 2021, 101(1):147-176.
[28] CHEN Y, ZHENG X, WU C. The role of the tumor microenvironment and treatment strategies in colorectal cancer[J]. Front Immunol, 2021, 12:792691.
[29] DE JAEGHERE E A, DENYS H G, DE WEVER O. Fibroblasts fuel immune escape in the tumor microenvironment[J]. Trends Cancer, 2019, 5(11):704-723.
[30] JAHANAFROOZ Z, MOSAFER J, AKBARI M, et al. Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment[J]. J Cell Physiol, 2020, 235(5):4153-4166.
[31] HASAN M N, CAPUK O, PATEL S M, et al. The role of metabolic plasticity of tumor-associated macrophages in shaping the tumor microenvironment immunity[J]. Cancers(Basel), 2022, 14(14):3331.
[32] SCOTT E N, GOCHER A M, WORKMAN C J, et al. Regulatory T cells: barriers of immune infiltration into the tumor microenvironment[J]. Front Immunol, 2021, 12:702726.
[33] TIAN Y, LI Y, SHAO Y, et al. Gene modification strategies for next-generation CAR T cells against solid cancers[J]. J Hematol Oncol, 2020, 13(1):54.
[34] GOLUBOVSKAYA V, BERAHOVICH R, ZHOU H, et al. CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth[J]. Cancers (Basel), 2017, 9(10):139.
[35] WILKIE S, VAN SCHALKWYK M C, HOBBS S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling[J]. J Clin Immunol, 2012, 32(5):1059-1070.
[36] CARUANA I, SAVOLDO B, HOYOS V, et al. Hepara-nase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes[J]. Nat Med, 2015, 21(5):524-529.
[37] WANG L C, LO A, SCHOLLER J, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity[J]. Cancer Immunol Res, 2014, 2(2):154-166.
[38] HILTBRUNNER S, BRITSCHGI C, SCHUBERTH P, et al. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase Ⅰ clinical trial[J]. Ann Oncol, 2021, 32(1):120-121.
[39] BURGA R A, THORN M, POINT G R, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T[J]. Cancer Immunol Immunother, 2015, 64(7):817-829.
Options
Outlines

/

〈 〉